Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22304008 | 0.77 | CYP17A1 (0.38) | CYP17A1CD44DRD2DRD3ACHE | |
| SCHEMBL22304321 | 0.77 | ACHE (0.30) | ACHE | |
| SCHEMBL29758607 | 0.76 | CYP17A1 (0.36) | CYP17A1 | |
| SCHEMBL15903440 | 0.74 | CYP17A1 (0.34) | CYP17A1DRD2HTR2ADRD3KCNH2 | |
| SCHEMBL23175352 | 0.72 | DRD2 (0.39) | CYP17A1HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL23175432 | 0.69 | DRD2 (0.42) | HTR1ADRD2HTR2AKCNH2ACHE | |
| SCHEMBL15920223 | 0.69 | CYP17A1 (0.32) | CYP17A1 | |
| SCHEMBL17279081 | 0.67 | DRD2 (0.31) | CYP17A1DRD2HTR2AKCNH2 | |
| SCHEMBL17279077 | 0.65 | RET (0.30) | — | |
| SCHEMBL15903523 | 0.64 | STAT1 (0.39) | CYP17A1HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | CYP17A1 2729/4885CD44 246/4885HTR1A 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.